In yesterday’s Wall Street session, Myriad Genetics Inc. (NASDAQ:MYGN) shares traded at $14.60, up 0.27% from the previous session.
MYGN stock price is now -21.48% away from the 50-day moving average and -30.98% away from the 200-day moving average. The market capitalization of the company currently stands at $1.23B.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
With the price target of $22, Stephens recently initiated with Equal-Weight rating for Myriad Genetics Inc. (NASDAQ: MYGN). , while ‘Raymond James’ rates the stock as ‘Mkt Perform’.
In other news, Riggsbee Richard Bryan, Chief Financial Officer sold 20,000 shares of the company’s stock on Dec 27. The stock was sold for $302,992 at an average price of $15.15. Upon completion of the transaction, the Chief Financial Officer now directly owns 374,107 shares in the company, valued at $5.46 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 06, Director SPIEGELMAN DANIEL K sold 6,424 shares of the business’s stock. A total of $123,673 was realized by selling the stock at an average price of $19.25. This leaves the insider owning 33,980 shares of the company worth $0.5 million. Insiders disposed of 251,053 shares of company stock worth roughly $3.67 million over the past 1 year. A total of 3.00% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in MYGN stock. A new stake in Myriad Genetics Inc. shares was purchased by MILLENNIUM MANAGEMENT LLC during the first quarter worth $18,487,000. GREAT WEST LIFE ASSURANCE CO /CAN/ invested $1,490,000 in shares of MYGN during the first quarter. In the first quarter, CANDRIAM S.C.A. acquired a new stake in Myriad Genetics Inc. valued at approximately $645,000. AMALGAMATED FINANCIAL CORP. acquired a new stake in MYGN for approximately $522,000. ALPHACREST CAPITAL MANAGEMENT LLC purchased a new stake in MYGN valued at around $441,000 in the second quarter.
Thursday morning saw Myriad Genetics Inc. (NASDAQ: MYGN) opened at $14.53. During the past 12 months, Myriad Genetics Inc. has had a low of $14.53 and a high of $28.45. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.70, and a quick ratio of 2.60. The fifty day moving average price for MYGN is $18.59 and a two-hundred day moving average price translates $21.15 for the stock.
The latest earnings results from Myriad Genetics Inc. (NASDAQ: MYGN) was released for Jun, 2022. According to the Diagnostics & Research Company, earnings per share came in at $0.04, beating analysts’ expectations of $0.01 by 0.03. This compares to $0.30 EPS in the same period last year. The net profit margin was -11.70% and return on equity was -8.20% for MYGN. The company reported revenue of $156.4 million for the quarter, compared to $167.3 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -6.52 percent. For the current quarter, analysts expect MYGN to generate $170.1M in revenue.
Myriad Genetics Inc.(MYGN) Company Profile
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women’s and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
